Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review

COMMENTED

Diabetes - General

Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk

Eur Heart J.

Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S

doi: 10.1093/eurheartj/ehz149.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use

JAMA Intern Med.

Karter AJ, Warton EM, Lipska KJ, Ralston JD, Moffet HH, Jackson GG, Huang ES, Miller DR

doi: 10.1001/

Diabetes - GeneralType 2 Diabetes

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

Diabetes Care.

Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators

doi: 10.2337/dc18-1094.

Diabetes - GeneralType 2 Diabetes

Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial

Diabetes Care.

Basu S, Raghavan S, Wexler DJ, Berkowitz SA

doi: 10.2337/dc17-2252.

Lipids

Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk

High Blood Press Cardiovasc Prev.

Agabiti Rosei E, Salvetti M

doi: 10.1007/s40292-016-0155-2

Type 2 DiabetesDiabetic Complications

SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials

Diabetes Obes Metab.

Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K, Sun X

doi: 10.1111/dom.14075.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials

Int J Cardiol.

Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B

doi: 10.1016/j.ijcard.2016.08.273.

Type 2 Diabetes

High-risk coronary artery plaque in asymptomatic patients with type 2 diabetes: clinical risk factors and coronary artery calcium score

Cardiovasc Diabetol

Heinsen LJ, Pararajasingam G, Andersen TR, Auscher S, Sheta HM, Precht H, Lambrechtsen J, Egstrup K

doi: 10.1186/s12933-021-01350-2